ViewRay Appoints Industry Veteran James Alecxih as Chief Commercial Officer
Mr. Alecxih to Lead Company's Commercial Expansion CLEVELAND, Oct. 2, 2018 -- (Healthcare Sales &Marketing Network) -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image ... Devices, Oncology, Radiology, Personnel ViewRay, MRIdian, radiation therapy, radiotherapy
ConclusionFive-year local control and disease-specific survival rates of patients surgically treated for vaginal non-SCC were favorable. Therefore, surgery could be a safe and reasonable option for early-stage primary vaginal non-SCC.
gins Len W. Seymour Janet Lei-Rossmann Ionising radiation causes cell death through the induction of DNA damage, particularly double-stranded DNA (dsDNA) breaks. Evidence suggests that adenoviruses inhibit proteins involved in the DNA damage response (DDR) to prevent recognition of double-stranded viral DNA genomes as cellular dsDNA breaks. We hypothesise that combining adenovirus treatment with radiotherapy has the potential for enhancing tumour-specific cytotoxicity through inhibition of the DDR and augmentation of virus production. We show that EnAd, an Ad3/Ad11p chimeric oncolytic adenovirus currently being tri...
High dose-rate (HDR) brachytherapy is commonly administered as a boost to external beam radiation therapy (EBRT). Our purpose was to compare toxicity with increasingly hypofractionated EBRT in combination with a single 15 Gy HDR boost for men with intermediate-risk prostate cancer.
Abstract BACKGROUND: PATHFx is a clinical decision-support tool based on machine learning capable of estimating the likelihood of survival after surgery for patients with skeletal metastases. The applicability of any machine-learning tool depends not only on successful external validation in unique patient populations but also on remaining relevant as more effective systemic treatments are introduced. With advancements in the treatment of metastatic disease, it is our responsibility to patients to ensure clinical support tools remain contemporary and accurate. QUESTION/PURPOSES: Therefore, we sought to (1) ge...
Conclusions: The first interstitial and surface HDR brachytherapy for cutaneous squamous cell carcinoma of a finger interspace for hand function preservation is presented. The initial experience revealed that brachytherapy was tolerated but with notable acute and late side effects. Treatment did result in tumor shrinkage with organ preservation and function of two rays. A larger cohort of patients will be required for additional conclusions related to long-term clinical benefits in patients who refuse ray amputation. PMID: 32190070 [PubMed]
Conclusions: At the time of writing of this study, there were more than 12,000 medical linear accelerators in clinical use, and XMLC can prove itself useful wherever linac is equipped with MLC but cannot delivery latest techniques, such as volumetric modulated arc therapy.
The incidence of thyroid cancer has been on the rise in recent decades with approximately 90% of these being differentiated thyroid carcinomas (DTCs) (including papillary and follicular). The majority of DTCs have a good prognosis and are potentially curable with standard treatment, the cornerstone of which is thyroidectomy. Commonly, patients may also receive adjuvant thyroid stimulating hormone suppression or radioactive iodine-131 (RAI). Due to a lack of randomized clinical trials, the role of adjuvant external beam radiation therapy (EBRT) in DTC is not well-established.
The impending implementation of the Radiation Oncology Alternative Payment Model (APM) is poised to initiate dramatic disruption in the financial incentives associated with radiation oncology practice, reversing previous incentives for increased fractionation and moving toward incentivizing brevity of care.1 Such incentivization theoretically favors treatment modalities such as hypofractionation and stereotactic body radiation therapy over traditional external beam radiation therapy (EBRT), provided they can yield comparable outcomes to EBRT.
ConclusionsClinical trials and approved treatments are lacking for unresectable DTC. TKI treatment may allow prolonged disease control with acceptable toxicity.
Abstract An 85-year-old asymptomatic man with suspected biochemical recurrence of prostate cancer underwent an F-fluciclovine PET/CT scan, which revealed a solitary suspicious tracer uptake in the dorsal right corporal body of the proximal pendulous penis. The patient underwent ultrasound-guided fine-needle aspiration of the penile lesion, which revealed metastatic prostate cancer. The patient had definitive external beam radiation therapy 3 years before the examination. At the time of scan, the prostatic-specific antigen (PSA) was only 1.0 ng/mL, although the PSA doubling time was 2.6 months. It is unusual to det...